Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Account Payables (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Change in Account Payables data on record, last reported at $6.7 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 6510.48% year-over-year to $6.7 million; the TTM value through Dec 2025 reached -$1.7 million, down 176.0%, while the annual FY2025 figure was -$1.7 million, 176.0% down from the prior year.
  • Change in Account Payables reached $6.7 million in Q4 2025 per ARQT's latest filing, up from -$9.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.7 million in Q4 2025 and bottomed at -$9.3 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $274850.0, with a median of $263000.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: plummeted 1931.34% in 2023, then skyrocketed 6510.48% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $2.4 million in 2021, then tumbled by 92.39% to $182000.0 in 2022, then crashed by 755.49% to -$1.2 million in 2023, then soared by 91.2% to -$105000.0 in 2024, then surged by 6510.48% to $6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $6.7 million in Q4 2025, -$9.3 million in Q3 2025, and $554000.0 in Q2 2025.